Skip to main content

New clinical guidelines have been announced for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, served as the co-chair of the ASCO/CCO expert panel that developed the guideline.

image2
Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger

The guideline, Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline, was published today in the Journal of Clinical Oncology.

As stated in the ASCO release, “We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years,” said Basch. “There are a lot of nuances about treatment selection in terms of disease stage and what prior therapies the patient received. We hope this guideline will help doctors and patients make informed treatment decisions.”